8-K: Onconetix Prepares for Nasdaq Listing with Pro Forma Financials Following Proteomedix Acquisition

Onconetix, Inc. has released pro forma financial statements reflecting the acquisition of Proteomedix and a pending conversion of preferred stock, as it seeks a Nasdaq listing.

Summary

• Onconetix, Inc. is preparing for a Nasdaq listing and has released pro forma financial statements to reflect the acquisition of Proteomedix AG.
• The pro forma financials include the impact of the issuance of 269,672,900 shares of common stock upon conversion of Series B Preferred Stock.
• The financials also account for the assumption and conversion of Proteomedix stock options and a $5 million private placement financing.
• The company is also accounting for the receipt of $922,749 from the issuance of 7,458,642 shares of common stock through the exercise of preferred investment options.
• Additionally, the pro forma statements include the potential issuance of up to 5,709,935 shares of common stock upon conversion of Series A Preferred Stock and up to 20,512,877 shares for the settlement of a related party debenture.
• The pro forma balance sheet shows total assets of $60,386,704 and total liabilities of $18,975,561.
• The pro forma net loss for the six months ended June 30, 2024, is $25,572,552, or $0.08 per share.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is progressing with its Nasdaq listing and has completed a significant acquisition, the substantial pro forma net loss and accumulated deficit are concerning. The sentiment is therefore cautiously negative.

Positives

• The pro forma financials provide transparency into the impact of the Proteomedix acquisition and the pending conversion of preferred stock.
• The company has secured $5 million in private placement financing.
• The company has received $922,749 from the exercise of preferred investment options.
• The company is moving forward with its Nasdaq listing application.

Negatives

• The company reported a pro forma net loss of $25,572,552 for the six months ended June 30, 2024.
• The company has a significant accumulated deficit of $82,358,746.
• The company has a large amount of liabilities at $18,975,561.

Risks

• The company needs to satisfy all of Nasdaq's initial listing criteria and complete the initial listing process.
• The pro forma financial information is based on assumptions and estimates and may not be indicative of future results.
• The company's financial position is impacted by a significant accumulated deficit and net losses.
• The company is subject to the risks associated with the biotechnology industry.

Future Outlook

The company is focused on completing its Nasdaq listing and integrating Proteomedix. The pro forma financials are based on the assumption that the shareholder vote on September 5, 2024, will be successful.

Management Comments

• The pro forma financial information is prepared for informational purposes only and is based on assumptions and estimates considered appropriate by management.

Industry Context

This announcement is relevant to the biotechnology industry, where mergers and acquisitions are common. The company's focus on men's health and oncology positions it in a growing market segment. The Nasdaq listing is a significant step for the company's growth and visibility.

Comparison to Industry Standards

• It is difficult to compare Onconetix directly to other companies without more specific information on their pipeline and stage of development.
• However, the pro forma net loss of $25.5 million for six months is significant and would be considered high for a company of this size.
• The company's accumulated deficit of $82.3 million is also a concern and would be considered high compared to other companies in the same stage of development.
• The company's total assets of $60.3 million is relatively low compared to other companies seeking a Nasdaq listing.
• The company's total liabilities of $18.9 million is also relatively high compared to other companies in the same stage of development.

Related Party Transactions

• The pro forma financials include the settlement of a related party debenture for 20,512,877 shares of common stock.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the issuance of new shares.
• Employees may be impacted by the integration of Proteomedix.
• Customers may benefit from the company's expanded product offerings.
• Creditors may be concerned about the company's financial position.

Next Steps

• The company will hold an annual meeting of stockholders on September 5, 2024, to vote on the issuance of shares related to the Series B Preferred Stock conversion and the private placement.
• The company will need to complete Nasdaq's initial listing process.
• The company will need to integrate Proteomedix into its operations.

Key Dates

Keywords

Onconetix, Proteomedix, Nasdaq listing, pro forma financials, Series B Preferred Stock, private placement, share exchange, biotechnology, merger, acquisition